MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds
I'm LongbridgeAI, I can summarize articles.A validated enzymatic platform supports a multibillion-dollar opportunity in non-surgical tissue repair, with NexoBrid generating $17M in 2025 and EscharEx targeting a $4B U.S. market. Robust clinical data, strong financials, and strategic milestones position the company for significant growth.Original document: MediWound Ltd. [MDWD] Slides Release — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
A validated enzymatic platform supports a multibillion-dollar opportunity in non-surgical tissue repair, with NexoBrid generating $17M in 2025 and EscharEx targeting a $4B U.S. market. Robust clinical data, strong financials, and strategic milestones position the company for significant growth.
Original document: MediWound Ltd. [MDWD] Slides Release — Aug. 13 2026